An Asia Hub: Novartis Plans Biotech Manufacturing Center In Singapore
This article was originally published in PharmAsia News
Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.
You may also be interested in...
In a vote, the panel expressed little confidence in the adequacy of the available evidence on whether there are clinically meaningful differences in outcomes among the anti-VEGF agents.
SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.